Adoptive transfer of anti-CD19 CAR or anti-CD123 CAR lymphocytes led to a significant anti-tumor response in B-ALL and acute myeloid leukemia (AML) disseminated disease models, respectively. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.